Clinical experience with XXXX : the first 107 @entity1 .

@entity1 @entity323 @entity2003 @entity390 @entity20837
PURPOSE: We assessed the efficacy and safety of @entity20837 in @entity1 with @entity323 . MATERIALS AND METHODS: A total of 107 @entity1 who had consultations because of @entity323 between July and November 2001 were assessed. The sample was randomly selected. RESULTS: Response to @entity20837 was assessed in 107 @entity1 complaining of @entity323 , randomly selected at the office. With the 2 mg initial dose the response amounted to 23.5%, with 3 mg it amounted to 28.5% and the global response to the drug amounted to 26.1%. Positive response was obtained in 18.5% of those in whom the dose was increased from 2 to 3 mg. Obtaining an erection with enough @entity2003 to enable coitus satisfactory for the @entity1 was accepted as a positive response. According to the clinical presentation of the @entity323 , the highest efficacy was found in those cases with early detumescence, and the lowest one in those cases with complete affection. The overall incidence of adverse effects was 8.4%, with @entity390 being the most frequently reported. CONCLUSIONS: @entity20837 is the first central action erection inducing drug. Its use is encouraged by high tolerability, low rate of adverse effects and virtually nonexistent interaction with other drugs usually administered to @entity1 with @entity323 .
